Keen‐Hun Tai

2.4k total citations · 1 hit paper
23 papers, 1.6k citations indexed

About

Keen‐Hun Tai is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Surgery. According to data from OpenAlex, Keen‐Hun Tai has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 7 papers in Radiation and 6 papers in Surgery. Recurrent topics in Keen‐Hun Tai's work include Prostate Cancer Diagnosis and Treatment (20 papers), Prostate Cancer Treatment and Research (19 papers) and Advanced Radiotherapy Techniques (7 papers). Keen‐Hun Tai is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (20 papers), Prostate Cancer Treatment and Research (19 papers) and Advanced Radiotherapy Techniques (7 papers). Keen‐Hun Tai collaborates with scholars based in Australia, New Zealand and United States. Keen‐Hun Tai's co-authors include Allison Steigler, James W. Denham, David S. Lamb, David Joseph, Chris Atkinson, Nigel Spry, David Christie, Sandra Turner, Catherine D’Este and John Matthews and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Keen‐Hun Tai

23 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

2011 299 citations James W. Denham, Allison Steigler et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keen‐Hun Tai Australia	12	1.4k	447	265	192	189	23	1.6k
David S. Lamb New Zealand	15	1.4k 1.0×	350 0.8×	294 1.1×	232 1.2×	160 0.8×	40	1.6k
Eliahu Gez Israel	12	867 0.6×	259 0.6×	107 0.4×	164 0.9×	149 0.8×	51	1.1k
Phillip Rubin United States	4	983 0.7×	264 0.6×	158 0.6×	91 0.5×	67 0.4×	10	1.1k
John Matthews Australia	14	755 0.5×	256 0.6×	89 0.3×	149 0.8×	158 0.8×	25	1.0k
Edward Adamovich United States	23	1.6k 1.2×	528 1.2×	57 0.2×	131 0.7×	179 0.9×	79	1.8k
Michelle H. Braccioforte United States	18	662 0.5×	132 0.3×	106 0.4×	121 0.6×	59 0.3×	52	786
Kerri Cote United States	16	1.0k 0.7×	164 0.4×	28 0.1×	158 0.8×	157 0.8×	22	1.2k
Jacques Laverdière Canada	10	674 0.5×	525 1.2×	41 0.2×	167 0.9×	294 1.6×	10	1.1k
A.V. D’Amico United States	7	812 0.6×	121 0.3×	36 0.1×	119 0.6×	85 0.4×	16	924
Rachel C. Morgan United Kingdom	7	936 0.7×	625 1.4×	24 0.1×	110 0.6×	186 1.0×	12	1.1k

Countries citing papers authored by Keen‐Hun Tai

Since Specialization

Citations

This map shows the geographic impact of Keen‐Hun Tai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keen‐Hun Tai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keen‐Hun Tai more than expected).

Fields of papers citing papers by Keen‐Hun Tai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keen‐Hun Tai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keen‐Hun Tai. The network helps show where Keen‐Hun Tai may publish in the future.

Co-authorship network of co-authors of Keen‐Hun Tai

This figure shows the co-authorship network connecting the top 25 collaborators of Keen‐Hun Tai. A scholar is included among the top collaborators of Keen‐Hun Tai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keen‐Hun Tai. Keen‐Hun Tai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sengupta, C., Thomas Ravkilde, P.R. Poulsen, et al.. (2022). The dosimetric error due to uncorrected tumor rotation during real‐time adaptive prostate stereotactic body radiation therapy. Medical Physics. 50(1). 20–29. 5 indexed citations

Hofman, Michael S., Guy C. Toner, Nathan Lawrentschuk, et al.. (2022). Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. Cancer Imaging. 22(1). 58–58. 4 indexed citations

Denham, James W., David Joseph, David S. Lamb, et al.. (2018). Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. The Lancet Oncology. 20(2). 267–281. 69 indexed citations

Ng, Sweet Ping, Gillian Duchesne, Keen‐Hun Tai, et al.. (2016). Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate International. 5(1). 8–12. 7 indexed citations

Sridharan, Swetha, Allison Steigler, Nigel Spry, et al.. (2016). Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiotherapy and Oncology. 121(1). 98–102. 32 indexed citations

Wu, Raymond, Anne Capp, Gary Cowin, et al.. (2015). A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiation Oncology. 10(1). 243–243. 7 indexed citations

Denham, James W., David Joseph, David S. Lamb, et al.. (2014). Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. The Lancet Oncology. 15(10). 1076–1089. 117 indexed citations

Lehman, Margot, Mark Sidhom, Andrew Kneebone, et al.. (2013). FROGG high‐risk prostate cancer workshop: Patterns of practice and literature review. Part II post‐radical prostatectomy. Journal of Medical Imaging and Radiation Oncology. 58(3). 392–400. 4 indexed citations

Denham, James W., Allison Steigler, Keen‐Hun Tai, et al.. (2013). Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiotherapy and Oncology. 107(2). 123–128. 4 indexed citations

10.

Nguyen, Brandon, Tomas Kron, Jim Cramb, et al.. (2012). Optimising the dosimetric quality and efficiency of post‐prostatectomy radiotherapy: A planning study comparing the performance of volumetric‐modulated arc therapy (VMAT) with an optimised seven‐field intensity‐modulated radiotherapy (IMRT) technique. Journal of Medical Imaging and Radiation Oncology. 56(2). 211–219. 6 indexed citations

11.

Khor, Richard, Gillian Duchesne, Keen‐Hun Tai, et al.. (2012). Direct 2-Arm Comparison Shows Benefit of High-Dose-Rate Brachytherapy Boost vs External Beam Radiation Therapy Alone for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 85(3). 679–685. 77 indexed citations

12.

Denham, James W., Allison Steigler, David S. Lamb, et al.. (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology. 12(5). 451–459. 299 indexed citations breakdown →

13.

Denham, James W., Mahesh Kumar, David S. Lamb, et al.. (2009). Recognizing False Biochemical Failure Calls After Radiation With or Without Neo-Adjuvant Androgen Deprivation for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 74(2). 404–411. 11 indexed citations

14.

Denham, James W., Allison Steigler, David S. Lamb, et al.. (2009). Why are pretreatment prostate‐specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?. Cancer. 115(19). 4477–4487. 20 indexed citations

15.

Denham, James W., Allison Steigler, Mahesh Kumar, et al.. (2009). Measuring Time to Biochemical Failure in the TROG 96.01 Trial: When Should the Clock Start Ticking?. International Journal of Radiation Oncology*Biology*Physics. 75(4). 1008–1012. 7 indexed citations

16.

Sidhom, Mark, Andrew Kneebone, Margot Lehman, et al.. (2008). Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiotherapy and Oncology. 88(1). 10–19. 137 indexed citations

17.

Denham, James W., Allison Steigler, David S. Lamb, et al.. (2008). Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. The Lancet Oncology. 9(11). 1058–1068. 70 indexed citations

18.

D’Amico, Anthony V., James W. Denham, Juanita Crook, et al.. (2007). Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions. Journal of Clinical Oncology. 25(17). 2420–2425. 371 indexed citations

19.

D’Amico, Anthony V., James W. Denham, M. Bolla, et al.. (2007). Short‐ vs long‐term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node‐negative high‐risk adenocarcinoma of the prostate. Cancer. 109(10). 2004–2010. 23 indexed citations

20.

Denham, James W., Allison Steigler, David S. Lamb, et al.. (2005). Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. The Lancet Oncology. 6(11). 841–850. 287 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact